Deprecated: Function get_magic_quotes_gpc() is deprecated in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 152

Notice: Undefined property: stdClass::$live in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 469

Notice: Undefined property: stdClass::$live in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 474

Notice: Undefined variable: type in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 560

Notice: Undefined variable: sortString in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 563
DEVICE MICROCURRENT

DEVICE MICROCURRENT

Brand Owner Address Description
NEUROPAX CES CRANIAL ELECTROTHERAPY STIMULATION NeuroDynamic Strategies 314 W. Main Street Kerrville TX 78028 This device is a microcurrent electrical stimulator called Cranial Electrotherapy Stimulator or CES It has been cleared by the FDA to be marketed for anxiety, depression, insomnia and other stress related disorders (G 010 A 9/1/95);NEUROPAX CES CRANIAL ELECTRONIC THERAPY STIMULATION;
 

Where the owner name is not linked, that owner no longer owns the brand

   
Technical Examples
  1. A method and apparatus for providing microcurrent stimulation (MSC) therapy. In accordance with the present invention, it has been determined that the application of microcurrent signals at particular frequencies to the eye for particular periods of time stabilizes and even improves conditions of macular degeneration and other ocular diseases. Experimental data from clinical trials shows that results of persons who underwent therapy are at least better than placebo (i.e., efficacious), and that the therapy is safe. In fact, experimental data from clinical trials showed that approximately 98% of the patients who underwent the MCS therapy of the invention experienced either stabilization or improvement of macular degeneration within one year of starting therapy. Of this percentage, approximately 65% of the patients subjected to the MCS therapy experienced improved vision, while approximately 32% experienced stabilization of macular degeneration (i.e., no further loss of vision).